Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.72 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21014255 | 0.96 | MGLL (0.80) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL15065220 | 0.96 | MGLL (0.80) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL31633417 | 0.96 | MGLL (0.80) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL4761624 | 0.88 | MGLL (0.58) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL407969 | 0.86 | MGLL (0.95) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL4761635 | 0.86 | MGLL (0.61) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL753123 | 0.85 | MGLL (0.76) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL4761628 | 0.84 | MGLL (0.63) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL15082420 | 0.84 | MGLL (1.00) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL140275 | 0.84 | MGLL (1.00) | MGLLFAAHPTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903035-A | Maleimide resin, process for producing the same, 3D-printable maleimide resin composition, process for producing the same, and device produced therefrom | 上海信斯帝克新材料有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-113717455-A | Resin composition, thermoplastic resin composite material, and thermoplastic resin article | 中国石油化工股份有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-107106450-B | Shaping keratin fibres using arabinose and ethylene carbonate | 宝洁公司 | 2020-12-01 | — | — | CN | claimed |
| US-12514926-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-01-06 | — | — | US | disclosed |
| US-12514928-B2 | Herboxidiene antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-01-06 | — | — | US | disclosed |
| US-20250135017-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-05-01 | — | — | US | disclosed |
| US-12172986-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD (JP) | 2024-12-24 | — | — | US | disclosed |
| US-20240360108-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-10-31 | — | — | US | disclosed |
| CN-117903035-A | Maleimide resin, process for producing the same, 3D-printable maleimide resin composition, process for producing the same, and device produced therefrom | 上海信斯帝克新材料有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11945807-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-04-02 | — | — | US | disclosed |
| CN-113717455-B | Resin composition, thermoplastic resin composite material, and thermoplastic resin article | 中国石油化工股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090012241-A1 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432330-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360108-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, RBM22, SF3B1 | MGLL 4600/4885FAAH 4427/4885PTGS1 3783/4885 |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | MGLL 3265/4885FAAH 3529/4885PTGS1 2931/4885 |
| US-11945807-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | MGLL 4600/4885FAAH 4427/4885PTGS1 3783/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | MGLL 1573/4885FAAH 3126/4885PTGS1 1536/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | MGLL 544/4885FAAH 1570/4885PTGS1 1789/4885 |
| US-12172986-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | MGLL 4600/4885FAAH 4427/4885PTGS1 3783/4885 |
| US-20250135017-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, SNRPE, HNRNPAB | MGLL 4708/4885FAAH 4513/4885PTGS1 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.